Biotechnology M&A » By The Online Investor Staff, updated Tue., Apr. 20, 4:05 AM
Recent mergers and acquisitions in the Biotechnology M&A category.
| This Slide: #20 of 83 |
Slide #20. Agenus — 4-Antibody
Acquirer:
Agenus (NASDAQ:AGEN)
Acquiree:
4-Antibody
Details:
Agenus Inc. (NASDAQ:AGEN), a biopharmaceutical company developing novel immunotherapeutics, including a portfolio of checkpoint modulators (CPMs), anti-cancer vaccines and adjuvants, today completed the previously announced acquisition of 4-Antibody AG, a private European-based biopharmaceutical company.
Agenus is a clinical-stage immuno-oncology company engaged in the development of a pipeline of immune checkpoint antibodies, adoptive cell therapies and neoantigen cancer vaccines, to fight cancer. Co.'s antibody candidates are balstilimab (an anti-PD-1 antibody) and zalifrelimab (an anti-CTLA-4 antibody), which are in trials of balstilimab monotherapy and balstilimab/zalifrelimab combination for patients with second-line cervical cancer. Co. is also developing its proprietary anti-CTLA-4 antibody, AGEN1181, which is designed to expand the population of patients benefiting from anti-CTLA-4 therapy. Co.'s AgenTus Therapeutics, Inc. subsidiary focuses on allogeneic cell therapies.
AGEN SEC Filing Email Alerts Service
Open the AGEN Page at The Online Investor »
|
|||||||||||||||||||||
Open the AGEN Page at The Online Investor (in a new window) »
|
|
Avg. Broker Rec.
|
Strong Buy (4.00 out of 4) 99th percentile
(ranked higher than approx. 99% of all stocks covered)
Analysts' Target Price: AGEN Stock Forecast Based on Zacks ABR data; powered by Xignite |
